Compare IRT & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRT | ABCL |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.5B |
| IPO Year | 2009 | 2020 |
| Metric | IRT | ABCL |
|---|---|---|
| Price | $16.25 | $11.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $20.45 | $8.40 |
| AVG Volume (30 Days) | 2.1M | ★ 9.1M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | ★ 41.18 | 10.91 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $657,696,000.00 | $75,128,000.00 |
| Revenue This Year | $3.21 | N/A |
| Revenue Next Year | $3.54 | $21.85 |
| P/E Ratio | $1,632.00 | ★ N/A |
| Revenue Growth | 2.76 | ★ 160.56 |
| 52 Week Low | $14.60 | $2.75 |
| 52 Week High | $18.19 | $12.58 |
| Indicator | IRT | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 42.69 | 62.36 |
| Support Level | $16.18 | $3.39 |
| Resistance Level | $16.93 | $12.58 |
| Average True Range (ATR) | 0.31 | 0.74 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 20.10 | 51.40 |
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Atlanta, Columbus, Dallas, Denver, Houston, Indianapolis, Nashville, Oklahoma City, Raleigh-Durham, and Tampa. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.